precursor T-cell acute lymphoblastic leukemia

disease

On this page

Also known as precursor T-cell acute lymphoblastic leukemia/lymphomaprecursor T-cell acute lymphocytic leukaemiaprecursor T-cell acute lymphocytic leukemiaprecursor T-cell acute lymphocytic leukemia/lymphomaT-ALL

Summary

precursor T-cell acute lymphoblastic leukemia (MONDO:0020512) is a cancer and 11 clinical trials. Top therapeutic interventions include fludarabine phosphate, isatuximab, and limantrafin. A subtype of acute lymphoblastic leukemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Classification: Cancer
Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	precursor T-cell acute lymphoblastic leukemia
Mondo ID	MONDO:0020512
EFO	EFO:1001830
Orphanet	99861
ICD-11	803161771
GARD	0019694
Is cancer (heuristic)	yes

Also known as: precursor T-cell acute lymphoblastic leukemia/lymphoma · precursor T-cell acute lymphocytic leukaemia · precursor T-cell acute lymphocytic leukemia · precursor T-cell acute lymphocytic leukemia/lymphoma · T-ALL

Data availability: 715 cell lines.

Disease family

This is a subtype of acute lymphoblastic leukemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › precursor lymphoblastic lymphoma/leukemia › acute lymphoblastic leukemia › precursor T-cell acute lymphoblastic leukemia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Nelarabine	Approved (phase 4)
Dexamethasone	Phase 3 (in late-stage trials)
Methotrexate	Phase 3 (in late-stage trials)
Pegaspargase	Phase 3 (in late-stage trials)
Vincristine	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	5
PHASE1/PHASE2	3
PHASE2	1
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06648889	PHASE2	RECRUITING	Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
NCT06911710	PHASE1/PHASE2	RECRUITING	The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
NCT03422679	PHASE1/PHASE2	TERMINATED	Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
NCT07585734	PHASE1/PHASE2	WITHDRAWN	Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia
NCT04318678	PHASE1	RECRUITING	CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
NCT06136364	PHASE1	RECRUITING	CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
NCT06909474	PHASE1	RECRUITING	Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
NCT05212584	PHASE1	UNKNOWN	CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
NCT05398614	PHASE1	UNKNOWN	SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies
NCT06849401	EARLY_PHASE1	NOT_YET_RECRUITING	The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia
NCT04785833	Not specified	UNKNOWN	CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUDARABINE PHOSPHATE	4	1
ISATUXIMAB	4	1
LIMANTRAFIN	2	1

Drugs: Fludarabine Phosphate, Isatuximab